A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2019-11-26 / J Transl Med 2019 Nov;17(1):391A phase I trial evaluating the safety and efficacy of weekly paclitaxel or cisplatin with electro-hyperthermia in patients with recurrent or persistent epithelial ovarian, fallopian tubal or primary peritoneal carcinoma (KGOG 3030).
/in Hyperthermia, International Publications, Ovarian Cancer /von 2019-05-31 / J Clin Oncol 37, 2019 (suppl; abstr e17032)Phase I/II clinical trial of modulated electro-hyperthermia treatment in patients with relapsed, refractory or progressive heavily treated ovarian cancer
/in Hyperthermia, International Publications, Ovarian Cancer /von 2019-05-09 / Jpn. J. Clin. Oncol. 2019 May;Personalized Dendritic Cell Vaccines-Recent Breakthroughs and Encouraging Clinical Results
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2019-04-11 / Front Immunol 2019;10:766Immunotherapy in Ovarian Cancer
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2019-04-05 / Surg. Oncol. Clin. N. Am. 2019 Jul;28(3):447-464Randomized phase II trial of patient-specific dendritic cell vaccines loaded with autologous tumor antigens versus autologous monocytes in patients with primary advanced ovarian cancer.
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2019-03-01 / J Clin Oncol 37, 2019 (suppl 8; abstr TPS10)Combined treatment with modulated electro-hyperthermia and an autophagy inhibitor effectively inhibit ovarian and cervical cancer growth
/in Cervical Cancer, Hyperthermia, International Publications, Ovarian Cancer /von 2018-11-14 / Int J Hyperthermia 2019;36(1):9-20Combining Vascular Normalization with an Oncolytic Virus Enhances Immunotherapy in a Preclinical Model of Advanced-Stage Ovarian Cancer
/in International Publications, Newcastle Disease Virus, Ovarian Cancer /von 2018-09-11 / Clin. Cancer Res. 2019 Mar;25(5):1624-1638Further clinical advancement of dendritic cell vaccination against ovarian cancer
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2018-08-23 / Ann Res Hosp 2018 Aug;2
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de